Demographic factors
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical or patient-reported
date
Height and weight are used to calculate BMI INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical reported RESPONSE OPTIONS: Numerical value of height in cm or in
integer
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical reported TYPE: Single answer
integer
Height and weight are used to calculate BMI INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical reported RESPONSE OPTIONS: Numerical value of weight in kg or lbs
integer
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical reported TYPE: Single answer
integer
Height and weight are used to calculate BMI INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Patient-reported RESPONSE OPTIONS: Numerical value of height in cm or in
integer
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Patient-reported TYPE: Single Answer
integer
Height and weight are used to calculate BMI INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Patient-reported RESPONSE OPTIONS: Numerical value of weight in kg or lbs
integer
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Patient-reported TYPE: Single answer
text
The level of schooling is defined in each country as per ISCED [International Standard Classification] INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
Baseline Clinical Factors
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical RESPONSE OPTIONS: Numerical value of hemoglobin level in g/L
integer
Based upon the Self-administered Comorbidity Questionnaire (Sangha et al, 2003) INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Patient-reported TYPE: Multiple answer Separate multiple entries with "";""
integer
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Patient-reported RESPONSE OPTIONS: Ordinal values from 0 to 10, with 'No pain' marked at '0' and 'Worst pain imaginable' marked at '10'
integer
A first degree relative is a father, brother, or son INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
Baseline Tumor Factors
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical RESPONSE OPTIONS: Numerical value of PSA ng/mL
integer
Pathologic staging preferred, if available cT0: No evidence of primary tumor cT1: if not able to select T1a, T1b or T1c: Clinically inapparent tumor neither palpable nor visible by imaging cT1a: Tumor incidental histologic finding in 5 percent or less of tissue resected cT1b: Tumor incidental histologic finding in more than 5 percent of tissue resected cT1c: Tumor identified by needle biopsy (eg, because of elevated PSA) cT2: if not able to select T2a, T2b or T2c: Tumor confined within prostate* cT2a: Tumor involves one-half of one lobe or less cT2b: Tumor involves more than one-half of one lobe but not both lobes cT2c: Tumor involves both lobes cT3: if not able to select T3a, T3b or T3c: Tumor extends through the prostate capsule cT3a: Extracapsular extension (unilateral or bilateral) cT3b: Tumor invades seminal vesicle(s) cT4: Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall cTX: Primary tumor cannot be assessed INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
integer
Pathologic staging preferred, if available cNo: regional lymph node metastasis cN1: Metastasis in regional lymph node(s) cNX: Regional lymph nodes were not assessed INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
integer
Pathologic staging preferred, if available pT2: if not able to select T2a, T2b or T2c: Organ confined pT2a: Unilateral, one-half of one side or less pT2b: Unilateral, involving more than one-half of side but not both sides pT2c: Bilateral disease pT3: if not able to select T3a, T3b: Extraprostatic extension pT3a: Extraprostatic extension or microscopic invasion of bladder neck pT3b: Seminal vesicle invasion pT4: Invasion of rectum, levator muscles, and/or pelvic wall pTX: Primary tumor cannot be assessed INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
integer
Pathologic staging preferred, if available pN0: No positive regional nodes pN1: Metastases in regional node(s) pNX: Regional nodes not sampled INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' on Gleason score (GLEASON) TIMING: Baseline REPORTING SOUCE: Clinical RESPONSE OPTIONS: 2-10
integer
INCLUSION CRITERIA: All patients If answered 'yes' on Gleason score (GLEASON) TIMING: Baseline REPORTING SOUCE: Clinical RESPONSE OPTIONS: 2-10
integer
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
integer
High burden is indicated as any of the following criteria (from: CHAARTED (randomized clinical trial in the US): - Visceral metastases (extranodal) - Bone metastases with at least 4 bone lesions OR at least 1 bone lesion outside of the vertebral column or pelvis. INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
integer
Treatment Factors
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' on prior prostatectomy (prostatectx) TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
date
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
integer
Use of any of the following treatments to induce castrate levels of serum testosterone: 1. LHRH or GnRH agonist or antagonist 2. Bilateral orchiectomies INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
integer
Any medication that treats the prostate cancer taken by mouth, through a vein, or injected, other than ADT INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
integer
Both anti-resorptive medications or denosumab are relevant INCLUSION CRITERIA: All patients TIMING: Baseline REPORTING SOUCE: Clinical TYPE: Single answer
integer
Treatment Variables
INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Single answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' on Androgen Deprivation Therapy (ADTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'yes' on Androgen Deprivation Therapy (ADTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'yes' on Androgen Deprivation Therapy (ADTX), and no end date is entered (ADTXSTOPDATE) TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Single answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' on hormonal therapy (HORMONTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'yes' on hormonal therapy (HORMONTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'yes' on hormonal therapy (HORMONTX), and no end date is entered (HORMONTXSTOPDATE) TIMING: Update at least annually REPORTING SOUCE: Clinical
integer
INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' on chemotherapy (CHEMOTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'yes' on chemotherapy (CHEMOTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'yes' on chemotherapy (CHEMOTX), and no end date is entered (CHEMOTXSTOPDATE) TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' on immunotherapy (IMMUNOTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'yes' on immunotherapy (IMMUNOTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'yes' on immunotherapy (IMMUNOTX), and no end date is entered (IMMUNOTXSTOPDATE) TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' on radiopharmaceuticals (RADIOPHARM) TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Single Answer
date
INCLUSION CRITERIA: All patients If answered 'yes' on radiopharmaceuticals (RADIOPHARM) TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Single Answer
date
INCLUSION CRITERIA: All patients If answered 'yes' on radiotherapy (RADIOTX), and no end date is entered (RADIOTXSTOPDATE) TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Single Answer
integer
Could be one of the following procedures: - TURP (transurethral resection of the prostate) - Ureteral stent - Percutaneous nephrostomy tube - Suprapubic catheter placement - Chronic foley catheter / self intermittent catheterization INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Multiple answer
integer
INCLUSION CRITERIA: All patients If answered 'TURP' on interventions for complications due to local progression (LOCPROGTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'ureteral stent' on interventions for complications due to local progression (LOCPROGTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'percutaneous nephrostomy tube' on interventions for complications due to local progression (LOCPROGTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'suprapubic catheter placement' on interventions for complications due to local progression (LOCPROGTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'chronic foley catheter / self intermittent catheterization' on interventions for complications due to local progression (LOCPROGTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' on bisphosphonates or denosumab (BISPHOSTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'yes' on bisphosphonates or denosumab (BISPHOSTX) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: All patients If answered 'yes' on bisphosphonates or denosumab (BISPHOSTX), and no end date is entered (BISPHOSTXSTOPDATE) TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Single Answer
integer
Acute Complications of Treatment
A CTCAE v 4 grace III complication or higher means that the patient had to be admitted to the hospital. See http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf for a list of domains and grades of complications INCLUSION CRITERIA: Patients with systemic therapy If answered 'yes' on chemotherapy, immunotherapy or hormonaltherapy (CHEMOTX or IMMUNOTX or HORMONTX) TIMING: Update at least annually REPORTING SOUCE: Clinical TYPE: Multiple answer
integer
INCLUSION CRITERIA: Patients with systemic therapy If answered 'Other' on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS) TIMING: Update at least annually REPORTING SOUCE: Clinical RESPONSE OPTIONS: CTCAE grade III-IV complication due to systemic therapy (excluding ADT)
text
INCLUSION CRITERIA: Patients with systemic therapy If answered Cytopenias on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: Patients with systemic therapy If answered Infection on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: Patients with systemic therapy If answered Vomiting, diarrhea, constipation, other GI toxicity on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: Patients with systemic therapy If answered Neuropathy on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: Patients with systemic therapy If answered Cardiovascular toxicity on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
INCLUSION CRITERIA: Patients with systemic therapy If answered Other on CTCAE grade III-IV complications due to systemic therapy (excluding ADT) (COMPLSYS) TIMING: Update at least annually REPORTING SOUCE: Clinical
date
Degree of health
ECOG / WHO scale: - PS = 0 normal activity level; - PS = 1 restricted with strenuous activity, but can do light activity; - PS = 2 active >/= 50% of day; - PS = 3 spends >50% of day in chair or bed; - PS = 4 totally confined to bed INCLUSION CRITERIA: All patients TIMING: Baseline 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Clinical TYPE: Single Answer
integer
ECOG / WHO scale: - PS = 0 normal activity level; - PS = 1 restricted with strenuous activity, but can do light activity; - PS = 2 active >/= 50% of day; - PS = 3 spends >50% of day in chair or bed; - PS = 4 totally confined to bed INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Multiple answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' to using medications or devices to aid or improve erections (LIBID_Q02)TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' to using medications or devices to aid or improve erections (LIBID_Q02) TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' to using medications or devices to aid or improve erections (LIBID_Q02)TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' to using medications or devices to aid or improve erections (LIBID_Q02) TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' to using medications or devices to aid or improve erections (LIBID_Q02) TIMING: Baseline 3 months post initiation of treatment 6 months post initiation of treatment 1 year post initiation of treatment Tracked ongoing annually for life REPORTING SOUCE: Patient-reported TYPE: Single answer
integer
EORTCQLQC
Survival and disease control
INCLUSION CRITERIA: All patients If answered 'yes' on procedures needed for local progression (LOCPROGTX) TIMING: 1 year post initiation of treatment Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Multiple Answer
integer
INCLUSION CRITERIA: All patients TIMING: 1 year post initiation of treatment Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' on symptomatic skeletal related event (SSRE) TIMING: 1 year post initiation of treatment Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical
date
INCLUSION CRITERIA: Patients without known metastasis TIMING: 1 year post initiation of treatment Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Single Answer
integer
INCLUSION CRITERIA: Patients without known metastasis If answered 'yes' on development of metastasis (METADEV) TIMING: 1 year post initiation of treatment Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical
date
Castration-resistant disease is defined as two successive PSA rises at least one week apart, or the development or progression of radiographically proven metastatic lesions, in the setting of castrate levels of testosterone (<50 ng/mL) INCLUSION CRITERIA: Patients that are not yet castration resistant TIMING: 1 year post initiation of treatment Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical TYPE: Single answer
integer
INCLUSION CRITERIA: Patients that are not yet castration resistant If answered 'yes' on development of castration-resistant disease (CRPCDATE) TIMING: 1 year post initiation of treatment Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Clinical
date
INCLUSION CRITERIA: All patients TIMING: 1 year post initiation of treatment Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Administrative data (Death registry) TYPE: Single answer
integer
INCLUSION CRITERIA: All patients If answered 'yes' on overall survival (OVERALLSURV) TIMING: 1 year post initiation of treatment Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Administrative data (Death registry)
date
INCLUSION CRITERIA: All patients If answered 'yes' on overall survival (OVERALLSURV) TIMING: 1 year post initiation of treatment Tracked ongoing annually for life (when hospital is able to track this ongoing) REPORTING SOURCE: Administrative data (Death registry) TYPE: Single answer
integer